



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : Mrs. Zarzokimi, (Assistant Drugs Inspector (Food and Drugs))
Champhai-796321 Mizoram
- Serial No. and date of Inspector's memorandum : 388/26 , 23-JAN-2026
- Number of Sample : NIL
- Date of receipt : 02-FEB-2026
- Names of drugs purporting to be contained in the sample : Telmisartan Tablets IP (Ezisartan-40)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/1227	GUW/LS/2025-26/1292	KT45-581E	Feb-2025 Jan-2027	NA	Krisa Healthcare, Plot No. 6, Apparel Park Cum Industrial Area, Katha, Tehsil Baddi, Distt. Solan (H.P.) - 173205

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 11-Feb-2026 To 11-Feb-2026

COMPOSITION : Each uncoated tablet contains:
Telmisartan IP 40 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, round shaped, bi-convex, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Telmisartan.	NA
3	Average weight	0.1694 g	NA
4	Uniformity of weight	Complies.	NA
5	Dissolution	Complies.	NLT 75 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Telmisartan	40.11 mg/Tablet	40 mg/Tablet	100.275	90 to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 16-MAR-2026

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----

